Supplementary Material (Online Only)

Supplementary Material (online only)

Supplementary Table S1. Studies Included in the Analysis (online only)

Study Citation Study Phase Study Population Chemotherapy Regimen Pegfilgrastim versus filgrastim RCTs Holmes et al., 2002 2 Breast doxorubicin + docetaxel Holmes et al., 2002 3 Breast doxorubicin + docetaxel Green et al., 2003 3 Breast doxorubicin + docetaxel Grigg et al., 2003 2 NHL CHOP Lopez et al., 2004 2 NHL CHOP-R Vose et al., 2003 2 NHLa ESHAP Johnston et al., 2000 2 NSCLC carboplatin + paclitaxel Pegfilgrastim versus no G-CSF RCTs Vogel et al., 2005 3 Breast docetaxel Romieu et al., 2007 2 Breast FEC-100 Hecht et al., 2010 2 Colorectal FOIL, FOLFOX4, FOLFIRI Smith et al., 2005 4 NSCLC carboplatin + paclitaxel + docetaxel Balducci et al., 2007 4 NHL, lung, breast, various or ovarian Same-day pegfilgrastim versus next-day pegfilgrastim studiesb Burris et al., 2010 2 NHL, breast, various ovarian, or lungc Single-arm studies Mattioli et al., 2009 2 Breast CMF George et al., 2003 2 NHL CHOP Wolf et al., 2006 2 NHL CHOP Pirker et al., 2006 2 SCLC ACE AMG 990736 (data on file) 2 Mixedd various AMG 20010137 (data on file) 2 Breast various aFour patients in this study had Hodgkin’s lymphoma but were grouped with the patients with NHL because they received ESHAP chemotherapy. bOnly patient data from the next-day arm were included in the analysis. cThese were four phase 2 studies that separately enrolled patients with NHL or breast, ovarian or lung cancer. dFive patients with tumor types reported as “other” were excluded. ACE, doxorubicin, cyclophosphamide, and etoposide; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisolone; CHOP-R, CHOP and rituximab; CMF, cyclophosphamide, methotrexate, 5-fluorouracil; ESHAP, etoposide, methylprednisolone, cisplatin, and cytarabine; FEC-100, 5-fluorouracil, epirubicin, and cyclophosphamide; FOIL, 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan; FOLFIRI, 5-fluorouracil, leucovorin, and irinotecan; FOLFOX4, 5-fluorouracil, leucovorin, and oxaliplatin; G-CSF, granulocyte colony-stimulating factor; NHL, non-Hodgkin’s lymphoma; RCTs, randomized controlled trials; SCLC, small-cell lung cancer.